中文 
别名:Fascin-3, Testis fascin, FSCN3应用:WB,IHC,FCM
反应种属:Human, Mouse
规格：50μl/100μl
| Description |
|---|
| FSCN3 acts as an actin bundling protein. |
| Specification | |
|---|---|
| Aliases | Fascin-3, Testis fascin, FSCN3 |
| Entrez GeneID | 29999 |
| Swissprot | Q9NQT6 |
| WB Predicted band size | 56.6kDa |
| Host/Isotype | Rabbit IgG |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | This Fascin-3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1-30 amino acids from the N-terminal region of human Fascin-3. |
| Formulation | Purified polyclonal antibody supplied in PBS with 0.05% sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS. |
| Application | |
|---|---|
| WB | 1/1000-1/8000 |
| IHC | 1/100-1/500 |
| FCM | 1/10-1/50 |
 |
Anti-Fascin-3 Antibody (N-term) at 1:8000 dilution + human testis lysate
Lysates/proteins at 20 µg per lane. Secondary Predicted band size : 57 kDa Blocking/Dilution buffer: 5% NFDM/TBST. |
 |
Western blot analysis of Fascin-3 Antibody (N-term) (Cat. #P33857) in MDA-MB231, NCI-H460 cell line and mouse testis tissue lysates (35ug/lane). Fascin-3 (arrow) was detected using the purified Pab. |
 |
Fascin-3 Antibody (N-term) (Cat. #P33857) flow cytometric analysis of MDA-MB231 cells (right histogram) compared to a negative control cell (left histogram).FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis. |
 |
Fascin-3 Antibody (N-term) (Cat. #P33857) IHC analysis in formalin fixed and paraffin embedded human testis tissue followed by peroxidase conjugation of the secondary antibody and DAB staining. This data demonstrates the use of the Fascin-3 Antibody (N-term) for immunohistochemistry. Clinical relevance has not been evaluated. |
本公司的所有产品仅用于科学研究或者工业应用等非医疗目的，不可用于人类或动物的临床诊断或治疗，非药用，非食用。
暂无评论
本公司的所有产品仅用于科学研究或者工业应用等非医疗目的，不可用于人类或动物的临床诊断或治疗，非药用，非食用。
发表回复